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Abstract
Introduction: Acute kidney injury (AKI) is common in neonatal intensive care units (NICU). In recent years, every effort is made for early detection 
of AKI. Our hypothesis was that serum neutrophil gelatinase-associated lipocalin (sNGAL) may be a reliable screening test for early diagnosis of AKI 
in premature neonates after perinatal asphyxia. Therefore, our aim was to assess the diagnostic accuracy of sNGAL for AKI in premature asphyxiated 
neonates.  
Materials and methods: AKI was defined in the third day of life (DOL 3) as a serum creatinine (sCr) increase ≥ 26.5 μmol/L from baseline (the 
lowest previous sCr). According to the increase of sCr, AKI patients were divided in AKIN1 (sCr increase up to 1.9 baseline) and AKIN2 (sCr increase 
from 2.0 to 2.9 baseline). sNGAL levels were measured on DOL 1, 3 and 7. 
Results: AKI was diagnosed in 73 (0.676) of 108 enrolled premature asphyxiated neonates. Sixty one patients (0.836) were classified in AKIN1 and 12 
patients (0.164) in AKIN2. sNGAL reached the maximal concentrations on DOL 1 within 4 hours after admission to NICU, being higher in AKI compared 
with no-AKI group (160.8 ± 113.1 vs. 87.1 ± 81.6; P < 0.001) as well as in AKIN2 compared with AKIN1 group (222.8 ± 112.9 vs. 147.8 ± 109.9; P < 
0.001). The best areas under the receiver operating characteristic curves (AUC) for prediction of AKI were 0.72 [95% (0.62-0.80) P < 0.001] on DOL1 at 
2h and 0.72 [95% (0.63-0.80) P < 0.001] at 4th hour after admission respectively. The corresponding sNGAL cutoff concentrations were 84.87 ng/mL 
(sensitivity 69.0% and specificity 71.9%) and 89.43 ng/mL (sensitivity 65.7% and specificity 74.3%).
Conclusions: In premature asphyxiated neonates sNGAL measured within the first 4 hours of DOL 1 is predictive of the occurrence and severity of 
AKI. Therefore, plasma levels of NGAL may be used for early diagnosis of AKI in these patients.
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Incidence of acute kidney injury (AKI) is the high-
est during the first month of life as newborn’s kid-
neys are more susceptible to injury (1-3). The inci-
dence rate for AKI in the Institute for neonatology 
in Belgrade, where this study was performed has 
been estimated to be about 30% of newly admit-
ted newborns per year. AKI is common complica-
tion in asphyxiated neonates with prevalence up 
to 70% in the neonatal intensive care units (NICU) 
(1,2). 
The current practice in the diagnosis of AKI is 
based on conventional biomarkers, serum creati-
nine (sCr) and urine output which are rather late 
and unreliable AKI markers (2,3). This diagnosis of 
AKI in newborns can be problematic due to many 
factors (3). During the first 48-72 h of life sCr still 
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reflects maternal levels (3-5). Further, in preterm 
infants with very low glomerular filtration rate, 
normal sCr concentrations vary greatly, depending 
on the level of prematurity and age (3-6). Further-
more, the diagnosis of AKI is delayed as sCr may 
not be changed until 25-50% of the kidney func-
tion has already been lost (3). Additionally, if Jaffe 
assay is used for sCr quantification, the results may 
be influenced by medications and hyperbiliru-
binemia (3). Finally, at lower renal function, sCr will 
overestimate renal function due to tubular secre-
tion of creatinine (3). Oliguria, defined as urine out-
put less than 1 mL / kg / h (3), is considered as an 
alternative or additional marker of AKI. We did not 
use urinary output for diagnosis of AKI. In neo-
nates, urinary output is unhelpful test as non-olig-
uric renal failure might be present in majority of 
cases (7). 
The delayed AKI diagnosis has an impact on the 
maintenance of high rates of AKI mortality in NICU 
(3,6). Therefore, great efforts are being made to 
find new biomarkers that enable early AKI diagno-
sis, within a few hours after the onset of kidney 
damage (3,6,8). One of the most promising AKI bi-
omarker is neutrophil gelatinase-associated 
lipocalin (NGAL) which is actually not so new (8-
13).
Diagnostic concentration of serum NGAL (sNGAL) 
has not yet been sufficiently investigated in pre-
mature neonates with perinatal asphyxia (PNA) 
(13).
Hypothesis of the present study was that serum 
neutrophil gelatinase-associated lipocalin (sNGAL) 
is a reliable screening test for early diagnosis of AKI 
in premature neonates after perinatal asphyxia. 
Therefore, our aim was to assess the diagnostic ac-
curacy of sNGAL for AKI in premature asphyxiated 
neonates.
Material and methods 
Subjects 
This cross-sectional diagnostic accuracy study was 
performed from January 2009 to December 2012 
in NICU of Institute for neonatology in Belgrade 
which is representative of the severe ill neonatal 
population in Serbia with approximately 980 an-
nual rates of patients.
Over the study period, there were 653 admissions 
of premature neonates with perinatal asphyxia to 
the NICU from which a total 108 patients were re-
cruited into the study (Figure 1). The premature 
neonates were included consecutively only if in-
formed consent was given and were admitted 
within one hour of birth with diagnosis of perina-
tal asphyxia that was set up by the experienced 
neonatologist. Perinatal asphyxia (PNA) was de-
fined as a failure to initiate sustained breathing at 
birth plus Apgar score (AS) of less than 7 in the 5th 
minute (14).
Five hundred fifty patients were screened for neo-
natal and maternal excluding reasons. Three hun-
dred eighty neonates with one or more of the fol-
lowing findings were excluded from the study: 
known renal or any other congenital anomalies, 
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Figure 1. Flow chart showing the patient recruitment process.
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ceiving diuretics and other drugs that can affect 
kidney (the first 48h), or if they did not survive be-
yond the first 3 days of life.
The purpose of the above listed analyses was to 
evaluate the health status of patients and that in 
the case of sepsis, hyperbilirubinemia, or existing 
renal disease they would be excluded from the 
study. The study lasted for a long time due to 
strictly adherence to inclusion and exclusion crite-
ria which ruled out a large number of premature 
children with asphyxia from recruitment into the 
study (Figure 1). Eighty seven newborns whose 
mother had chronic kidney disease, hypertension, 
severe systemic disease, diabetes mellitus or some 
other chronic disease were also excluded from the 
research to eliminate the adverse impact of their 
illness on infant stress and kidney function. Data 
on the health of mothers were obtained through 
retrospective review of medical records of Gyne-
cology and Obstetrics Hospitals. Gestational age 
(GA) was determined by calculation from the last 
menstrual period and/or antenatal ultrasonogra-
phy and was confirmed by Ballard score in the 
postnatal period (15). Hypoxic ischemic encepha-
lopathy (HIE) was defined according to Saranat 
and Saranat (16). AKI was defined according to the 
contemporary definition modified for neonates, 
similar to Kidney Disease: Improving Global Out-
come (KDIGO) AKI definition by which a sCr rise by 
≥ 26.5 μmol/L (that is equal to 0.3 mg/dl) from 
baseline defines AKI in the third day of life (DOL 3). 
The lowest previous sCr serves as the baseline sCr 
(17,18). AKI patients were subsequently discrimi-
nated according to the increase of sCr into AKIN1 
(sCr increase up to 1.9 baseline) and AKIN2 (sCr in-
crease from 2.0 to 2.9 baseline) groups.
Methods
Laboratory investigations, including complete 
blood count, C-reactive protein, blood urea nitro-
gen, sCr and bilirubin were determined daily. Com-
plete blood count and C-reactive protein were 
measured from venous whole blood, using analyz-
er ABX Micros CRP200, Horiba, France. Urea and 
bilirubin were measured from serum samples: 
urea on Maxmat analyzer using Maxmat reagents 
(Maxmat S.A., Montellier, France), while bilirubin 
was determined on bilirubinometer Reichert Uni-
stat (Depew, NY, USA). Blood pH and base deficit 
(BD) were taken daily from capillary blood usually 
from heel foot and measured on gas analyzer Ra-
diometer, Copenhagen, Denmark. Venous blood 
samples were taken by micro tube without gel, Ep-
pendorf Safe-Lock Tubes™, 1.5 ml (Eppendorf, 
Hamburg, Germany), while 125 µL were taken, for 
blood gas analyses, by capillary tubes with hepa-
rin (3-A GLASS, Belgrade, Serbia).
For sNGAL venous blood samples (1.0-1.5 mL) were 
taken five times: on DOL 1 three times (2, 4 and 6 
hours after admission to NICU), and once on DOL 3 
and DOL 7. Blood samples were centrifuged at 
1000 x g for 10 minutes and the collected serum 
was stored at -80 ⁰C until assayed. Analysis of sN-
GAL was done using human-specific commercially 
available enzyme-linked immunoassays (ELISA) 
(R&D Systems, Inc., Minneapolis, Minnesota, USA) 
according to the manufacturer’s recommenda-
tions. Concentrations of sNGAL were expressed in 
ng/mL. Based on our results, analytical accuracy 
characteristics of the test were as follows: intra-as-
say coefficient of variation (CV) 3.7%, inter-assay 
CV 6.5%; linearity from 0.156 ng/mL - 10 ng/mL, 
with sensitivity of 0.012 ng/mL. We have per-
formed method intra and inter-assay precision de-
termination. The standard concentrations for this 
analysis were 5 ng/mL, 2.5 ng/mL and 1.25 ng/mL 
of recombinant human Lipocalin-2 substance 
(R&D Systems, Inc., Minneapolis, Minnesota, USA). 
Before every patient’s group analysis, we per-
formed analytical pilot study in order to determine 
the highest possible concentration and the best 
dilution ratio for the group. We have chosen the 10 
samples with the highest sCr concentrations and 
also find NGAL concentrations in literature on the 
similar population. We expected the highest con-
centrations about 300 ng/mL and used 1:20, 1:40, 
1:80 and 1:100 dilutions. Dilutions were performed 
with original R&D Systems Inc. Sample diluents re-
agent. We got the lowest CVs with 1:80 dilutions 
and this dilution we have used for further analy-
ses. For those samples which have concentrations 
below the lowest point at the standard curve, we 
repeated analysis with lower dilution, 1:40. Serum 
creatinine concentrations were measured using 
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Jaffe’s method (reagent produced by Human, 
Wiesbaden, Germany) on a Dimension auto ana-
lyzer (Siemens Healthcare GmbH, Germany using 
reagents Human, Wiesbaden, Germany). Intra-as-
say CVs was 2.0% and 1.34% for Cr concentrations 
of 122 μmol/L and 350 μmol/L, respectively. We 
have performed analyses every six months in or-
der to prevent inter-run variability. Stability of the 
NGAL according to Han et al. (19) is up to one year 
at -80 ⁰C and up to 11 months according to Ped-
ersen et al. (20).
Laboratory investigators were blinded to clinical 
outcomes. Urine output was systematically meas-
ured by collecting into plastic collecting bags or 
through a urinary catheter. Diuretics were not giv-
en to any patient during the first 48 hours. Oliguria 
was defined as urine output < 1mL / kg / hour (3). 
General supportive care was applied according to 
the NICU ś protocol. The length of mechanical 
ventilation and the NICU stay were recorded. This 
clinical and research activities were done accord-
ing the principles of the Declaration of Helsinki 
and the study was approved by Ethics committee 
of the School of Medicine University of Belgrade 
and Ethics committee of the Institute for Neona-
tology in Belgrade. Written consent was obtained 
from parents of the examined children. 
Statistical analysis 
The Kolmogorov-Smirnov test was used to assess 
types of distribution of investigated parameters. 
Normally distributed data were expressed as mean 
and respective standard deviations, while the non-
normally distributed data were expressed as me-
dian and corresponding interquartile range. Cate-
gorical variables were expressed as frequencies 
and percentages or relative values. Significance of 
between-group differences was tested by the par-
ametric independent t-test, nonparametric Mann-
Whitney test, and chi-square test where appropri-
ate. To compare sNGAL concentrations among the 
three groups (no-AKI, AKIN1 and AKIN2) the non-
parametric Kruskal-Wallis test was used. To com-
pare sNGAL concentrations trough time (2 hours, 4 
hours, 6 hours, day 3 and day 7) in each study 
group the non-parametric Friedman test has been 
used. The receiver operating characteristic (ROC) 
analysis was used to estimate diagnostic accuracy 
of sNGAL in discriminating between AKI and non-
AKI as well as between AKIN1 and AKIN2 neonates, 
i.e. to determine optimal cut-off concentrations, 
area under ROC curve (AUC), with respective 95% 
confidence intervals (95% CI), specificity and sensi-
tivity values, as well as likelihood positive and like-
lihood negative values along with their 95% confi-
dence intervals. All multivariate analyses were ad-
justed on the well-known confounders: gestation-
al age, gender, 5-min AS, birth body weight (BBW), 
and BD of the neonates. There were 5 models for 
assessing the potential independent effects of sN-
GAL concentrations in five different time points on 
AKI presence as well as 5 models for AKIN2 pres-
ence. Models are presented with odds ratios and 
theirs 95% confidence interval along with P. 
Statistical analyses were performed using IBM 
Corp. Realized 2013. IBM Statistics for Windows, 
Version 22.0 Armonk, NY: IBM. P < 0.05 was consid-
ered to be statistically significant.
Results
One hundred eight premature neonates of mean 
GA 34.15 (28.10-37.0) gestational weeks (gw) with 
BBW of 2214 ± 551 g and AS of 5.0 ± 1.6 were en-
rolled in study. Sepsis, or other infections or in-
flammatory status were excluded by normal CRP 
levels. Patientś  clinical characteristics are summa-
rized in Table 1. Seventy three patients (0.676) 
were classified in AKI group and the remaining 35 
patients (0.324) in no-AKI group. As expected by 
study design, AS was lower and BD higher in AKI 
than in no-AKI group. HIE was also more common 
in AKI than in no-AKI group, as there were a longer 
period of mechanical ventilation and hospital 
NICU length of stay in that group. Two lethal out-
comes were registered only in AKI group. From AKI 
patients 0.836 (N = 61) were grouped in AKIN1 and 
0.164 (N = 12) in AKIN2 group. Serum NGAL con-
centrations significantly changed during observa-
tion time points as shown in Table 2 and Fig 2. 
They were significantly higher in AKI compared 
with no-AKI patients on DOL 1 at 2, 4 and 6 hours 
after admission and in AKIN2 compared with 
AKIN1 at 4 hours after admission to NICU. Unfortu-
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Characteristics No-AKIN = 35
AKI




N = 12 P
Male/Female*** 31/4 35/38 0.911 26/35 9/3 0.812
Gestational age (weeks)* 33.9±1.9 33.9±1.9 0.059 33.8±2.1 34.1±1.8 0.650
Birth body weight (g)** 2195±551 2257±579 0.726 2204±535 2322±627 0.963
Apgar score, 5 min** 6.0 (4.0-7.0) 5.0 (4.0-6.0) 0.039 5.0 (4.0-6.0) 4.5 (3.0-6.8) 0.590
Base deficit (mmol/L)* 7.8±2.5 9.0±3.2 0.016 8.5±3.1 11.6±2.9 0.001
Oliguric patients*** 4/35 5/73 0.061 2/61 3/12 0.168
Hypoxic-ischemic encephalopathy*** 6/35 35/73 <0.001 25/61 10/12 <0.001
Mechanical ventilation (days)** 2.0 (0.0-3.0) 7.0 (5.0-10.0) <0.001 7.0 (5.0-9.0) 15.0 (7.2-20.2) 0.002
Hospital NICU length of stay (days)** 6.0 (4.0-7.0) 11.5 (5.0-18.0) <0.001 10.5 (5.0-18.0) 17.0 (7.0-23.0) <0.001
Alive on day 10 of life*** 35/35 71/73 0.066 61/61 10/12 <0.001
Basal serum Creatinine on DOL1 (µmol/L)** 96 (84-116) 102 (92-122) 0.037 104 (95-132) 92 (83-106) 0.026
Serum Creatinine DOL3 (μmol/L)** 108 (89-118) 160 (138-183) <0.001 157 (136-174) 189 (170-211) 0.010
Serum Creatinine DOL7 (μmol/L)** 98 (88-138) 134 (100-157) <0.001 133 (98-155) 156 (123-182) 0.038
DOL - day of life; DOL1 - The first day of life; DOL3 - The third day of life; DOL7 - The seventh day of life; NICU - neonatal intensive 
care unit; AKI - Acute kidney injury; No-AKI - without AKI; AKIN1 - Stage 1 of AKI; AKIN2 - Stage 2 of AKI.
*mean ± standard deviation; **Median (Interquartile- IQR range); ***ratio.






DOL12 66.6 (24.7-100.8) 98.9 (61.8-245.7) 128.0 (93.4-259.4) 0.001
DOL14 71.5 (28.2-98.4) 98.8 (70.6-224.0) 216.7 (113.3-340.1) <0.001
DOL16 68.1 (39.3-117.2) 108.6 (64.3-208.2) 151.5 (91.4-345.9) 0.003
DOL3 74.3 (43.3-104.2) 98.8 (67.3-98.8) 113.8 (90.0-207.4) 0.025
DOL7 78.5 (30.2-98.5) 80.1 (50.4-128.7) 107.1 (75.9-173.8) 0.055
P## 0.002 <0.001 0.002
Data are presented as median and interquartile range (IQR).
sNGAL - serum neutrophil gelatinase-associated lipocalin concentration; AKI - acute kidney injury; no-AKI - without 
AKI; AKIN1 - Stage 1 of AKI; AKIN2 - Stage 2 of AKI; DOL - day of life; DOL12 - 2 hours after admission in DOL1; DOL14 
- 4 hours after admission in DOL1; DOL16 - 6 hours after admission in DOL1; DOL3 - The third day of life; DOL7 - The 
seventh day of life.
# according to Kruskal-Wallis test; ## according to Friedman test.
Table 2. sNGAL in the premature neonates with and without acute kidney injury from day 1 to day 7.
nately, there are some missing results due to tech-
nical reasons (Table 3). The results of the diagnos-
tic accuracy of sNGAL in study time periods evalu-
ated by non-parametric ROC curves are presented 
in Tables 3 and 4. To predict AKI AUC was highest 
on DOL1 within the first 4 hours after admission to 
NICU, being even more significant when adjusted 
on known (or generated in this study with P ≤ 0.10) 
confounders such as gender, GA, 5-min AS, BBW, 
and BD. The best AUC for prediction of AKI were 
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sNGAL 
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sNGAL - serum neutrophil gelatinase-associated lipocalin concentration; AKI - Acute kidney injury; no-AKI - without AKI; AKIN1 - 
Stage 1 of AKI; AKIN2 - Stage 2 of AKI; DOL - day of life, DOL 12 - 2 hours after admission in DOL1; DOL 14 - 4 hours after admission in 
DOL1; DOL 16 - 6 hours after admission in DOL1; DOL3 - The third day of life; DOL7 - The seventh day of life; CI - confidence interval; 
(LR+) - Likelihood ratio positive; (LR-) - Likelihood ratio negative; AUC - area under the receiver-operating-characteristic curve.
# According to Hanley-McNeil test.
Table 3. Serum NGAL predictive accuracy for AKI and its severity.
0.72 [95% (0.62-0.80) P < 0.001] on DOL1 at 2 h and 
0.72 [95% (0.63-0.80) P < 0.001] at 4 hours after ad-
mission, respectively. 
The corresponding sNGAL cutoff concentrations 
were 84.9 (sensitivity 0.690 and specificity 0.719) 
and 89.4 ng/mL (sensitivity 0.657 and specificity 
0.743) (Table 3). A diagnostic concentrations of sN-
GAL as risk factor for AKI development was also 
confirmed with multivariate logistic regression 
analysis showing an increasing risk for AKI with in-
creasing concentrations of sNGAL on DOL 1, 3 and 
7 (Table 4).
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Dependent variables sNGAL
Multivariate model#
OR (95 % CI) P
AKI vs. no-AKI
sNGAL DOL 12 1.185 (0.000-7.139) 0.999
sNGAL DOL 14 1.012 (1.003-1.020) 0.007
sNGAL DOL 16 1.009 (1.002-1.015) 0.010
sNGAL DOL 3 1.006 (1.001-1.012) 0.030
sNGAL DOL 7 1.007 (1.000-1.014) 0.046
AKIN2 vs. AKIN1
sNGAL DOL 12 1.003 (0.996-1.010) 0.384
sNGAL DOL 14 1.005 (0.999-1.011) 0.117
sNGAL DOL 16 0.005 (0.998-1.012) 0.194
sNGAL DOL 3 1.006 (0.997-1.014) 0.191
sNGAL DOL 7 1.010 (1.000-1.021) 0.055
sNGAL - serum neutrophil gelatinase-associated lipocalin concentration; AKI - Acute kidney injury; no-AKI - without 
AKI; AKIN1 - Stage 1 of AKI; AKIN2 - Stage 2 of AKI; DOL - day of life; DOL 12 - 2 hours after admission in DOL1; DOL 14 
- 4 hours after admission in DOL1; DOL 16 - 6 hours after admission in DOL1; CI - confidence interval; OR - odds ratio.
# Adjusted for: gender, gestational age, 5-min Apgar score, birth body weight, base deficit.
Table 4. The association between sNGAL concetrations from day 1 to day 7 and development of acute kidney injury.
Discussion 
This study investigated the diagnostic accuracy of 
sNGAL in preterm neonates with perinatal asphyx-
ia without other risk factors that may have impact 
on renal function and/or on NGAL concentrations. 
Plasma NGAL is strongly influenced by inflamma-
tion. Therefore, in patients with any inflammation, 
diagnostic concentrations of sNGAL for the detec-
tion of AKI might be restricted. Further studies in 
NICU setting should develop biomarker panel 
which in combination with risk stratification, could 
differentiate patients admitted with sepsis from 
those admitted for other indications. We planned 
to include about 100 patients. Given that a large 
number of patients were not eligible for recruit-
ment due to strict compliance with inclusion and 
exclusion criteria, the study was extended to the 
fulfillment of the expected number of the eligible 
patients. NGAL was tested in serum, so as in urine. 
However, the scope of this article is devoted only 
to serum NGAL analysis as urine samples were not 
obtained in all patients in the first day of life due to 
delayed micturation after delivery.
We have confirmed our hypothesis that sNGAL 
may be marker of AKI in asphyxiated premature 
neonates. Serum NGAL level had a moderate dis-
criminatory power to predict sCr-based AKI with 
AUC of 0.72. What is also remarkably is that sNGAL 
may differentiate AKI from no AKI patients within 
the first 4 hours after perinatal asphyxia. This is 
very important from the point of the implementa-
tion of the early treatment of critically ill prema-
ture infants to improve their outcome (3,12). We 
found also that the risk of AKI occurrence and se-
verity increases with increased concentration of 
sNGAL. Interestingly, the prediction of AKI using 
sNGAL AUC was better for AKIN1 than for the 
whole AKI group that may be attributed to its bet-
ter sensitivity for earlier stages of AKI. Namely, as 
found by other authors (9,10,21), it could be ex-
pected that predictive values would increase 
when sNGAL is measured closer to the time of in-
sult.
Our results are in line with those from literature re-
garding NGAL (9-13,21-28). Since 2003, when 
Mishra et al. pointed importance of NGAL as an 
early AKI biomarker in children after cardiac sur-
gery (9), number of papers which reported the role 
of NGAL in predicting AKI has been rapidly in-
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creasing (10-13,21-28). Although the follow-up 
studies failed to show the outstanding perfor-
mance of the first trials (9), the implementation of 
NGAL in early AKI diagnosis in previously healthy 
patients without comorbidities remains very good 
(24). There are no many pediatric studies which 
have examined NGAL outside of the cardiopulmo-
nary bypass population and quite a few research-
ers have investigated the benefit of sNGAL in diag-
nosis of AKI in newborns. Krawczeski et al. exam-
ined serum and urine NGAL in 374 infants under-
going cardiopulmonary by-pass (CBP). Only 35 
were newborns and 5 (0.143) of them developed 
AKI. They found that NGAL predicted AKI at 2 
hours after CBP with AUC ranged 0.74-0.88 (10). In 
case control study of Sarafidis et al. (13) which in-
cluded 13 asphyxiated and 22 non-asphyxiated 
newborns, 8 patients had AKI. Serum NGAL, as 
well as urine NGAL and serum Cystatin C predicted 
better PNA than AKI as they were higher in as-
phyxiated neonates, even in those not developing 
AKI (13). Ragall et al. investigated sNGAL in 30 new-
borns with HIE of whom 13 (0.433) developed AKI 
(25). They found elevated sNGAL measured within 
6 hours after birth reliably indicates (AUC 0.968) 
AKI in asphyxiated neonates. Similar results, but 
with urinary NGAL (uNGAL) were reported by Es-
sajee et al. (27). They used uNGAL not only to pre-
dict serum creatinine-based AKI in asphyxiated 
premature neonates, but also to define AKI to as-
sociate a Day 1 uNGAL concentration above a spe-
cific threshold with clinical outcome (27,28). Finally 
Smertka et al. examined 73 newborns with sepsis 
and 29 without sepsis (26). Five sepsis patients 
(0.680) developed AKI. They concluded that NGAL 
more accurately reflect the severity of inflamma-
tory status than AKI (26). No one of our patients 
had sepsis or other documented infections or in-
flammatory status. Therefore, an increase of sN-
GAL may be attributed only to AKI. We used DOL 3 
sCr based definition of AKI having in mind that at 
that time sCr better reflects the kidney function in 
newborns. Serum creatinine concentrations meas-
ured in the first hours of life which were lower in 
AKI compared with those in no-AKI group may be 
explained by lower maternal sCr, and additionally 
confirms that patients from AKI group had no pre-
natal kidney damage. Like other authors (7,29) we 
didn’t find urine output to be useful for the diag-
nosis of AKI, as most of AKI patients were non-olig-
uric.
The strengths of this study include: first, the evalu-
ation of great population of preterm neonates 
with PNA; and second, the prospective nature of 
data collection and rigorous protocol for sam-
pling, which was followed by blind measurements 
of biomarkers. Third, the examination started in 
first or second hour of life, promptly after hypoxic-
ischemic insult. Finally, early identification with sN-
GAL of newborns who are at risk for developing 
AKI, or who already have AKI may contribute to im-
provement of their treatment and outcome. De-
spite these strengths, this study has many limita-
tions. The first one is that we used sCr as the gold 
standard for the diagnosis of AKI, although it is de-
layed marker of renal function and it does not rise 
until significant loss of renal function occurs. It is 
possible that some patients with “negative creati-
nine, NGAL positive” were misclassified in no-AKI 
group that could negatively affect  the diagnostic 
accuracy of sNGAL. We are also aware of the limi-
tation of Jaffe reactions to determine sCr. In addi-
tion, this study is limited by small simple size being 
a single-center study that needs validation at the 
larger group of patients at multicenter level. 
Furthermore, our results were obtained in select-
ed premature neonates with mild to moderate de-
gree of perinatal asphyxia without other neonatal 
and maternal risk factors, and therefore cannot be 
generalized on complete neonatal population, in-
cluding term neonates, who are significantly dif-
ferent from preterm ones in response to PNA and 
in susceptibility of developing AKI. Moreover, pa-
tients who died before 3 day of life were not in-
cluded, but in these patients early diagnosis of AKI 
is very important. At last, although we have dem-
onstrated that sNGAL may have a role in early 
stage AKI identification, it is still unclear how much 
sNGAL incorporation into clinical care will improve 
AKI outcome. Regarding that, the ELISA tests for 
sNGAL determination that we have used (because 
we do not have any other test for some automated 
analyzer system) are not suitable for urgent pa-
rameters determination, because this is long-term 
and time-consuming method. We hope that 
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health diagnostics manufacturer will develop 
some kind of immunochemical reagents which 
could be applied at automatic analyzer system.
Conclusions
In premature asphyxiated neonates sNGAL meas-
ured within the first 4 hours of DOL 1 is predictive 
of the occurrence and severity of AKI. Therefore, 
plasma levels of NGAL may be used for early diag-
nosis of AKI in these patients. By allowing earlier 
timing of injury and earlier intervention, it could 
improve AKI outcome. 
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